Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

INTRODUCTION: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Jeffrey C., Aggarwal, Charu, Wong, Janeline, Nimgaonkar, Vivek, Hwang, Wei-Ting, Andronov, Michelle, Dibardino, David M., Hutchinson, Christoph T., Ma, Kevin C., Lanfranco, Anthony, Moon, Edmund, Haas, Andrew R., Singh, Aditi P., Ciunci, Christine A., Marmarelis, Melina, D’Avella, Christopher, Cohen, Justine V., Bauml, Joshua M., Cohen, Roger B., Langer, Corey J., Vachani, Anil, Carpenter, Erica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980884/
https://www.ncbi.nlm.nih.gov/pubmed/35392653
http://dx.doi.org/10.1016/j.jtocrr.2022.100301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980884/
https://www.ncbi.nlm.nih.gov/pubmed/35392653
http://dx.doi.org/10.1016/j.jtocrr.2022.100301

Ejemplares similares